Nasdaq First North

Approval of Transfer of Icelandic Listing to Nasdaq Main Market

Retrieved on: 
Wednesday, September 13, 2023
Nasdaq First North, Iceland, Main Market, Onitsha, Gold, AIM, Cryptocurrency

TORONTO, ONTARIO – September 13, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), Icelandic reg.

Key Points: 
  • TORONTO, ONTARIO – September 13, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), Icelandic reg.
  • no 600122-9910, an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to note that the Nasdaq exchange has approved the Company’s application for the transfer of its shares to Nasdaq Iceland‘s Main market (the “Main Market”) from the Iceland First North Growth Market.
  • The Company’s Shares will be admitted to trading on the Main Market on September 21, 2023.
  • A link to the Nasdaq announcement is set out below:

Amaroq publishes Prospectus in connection with Listing on Nasdaq Main Market in Iceland

Retrieved on: 
Tuesday, September 12, 2023
Nasdaq First North, AIM, Central bank, Nasdaq Iceland, Financial Supervisory Authority (Iceland), Prospectus, Gold, Admission, Corporate finance, Central Bank of Iceland, Cryptocurrency

no 600122-9910, an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to announce the publication of a Prospectus in connection with its planned listing on the Nasdaq Main Market in Iceland (“Admission”).

Key Points: 
  • no 600122-9910, an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to announce the publication of a Prospectus in connection with its planned listing on the Nasdaq Main Market in Iceland (“Admission”).
  • The Prospectus, dated September 12, 2023 has been approved by the Financial Supervisory Authority of the Central Bank of Iceland.
  • Alongside publication of the Prospectus, the Company has applied to Nasdaq Iceland for Admission.
  • Nasdaq Iceland will announce the first day of trading with at least one day’s notice.

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 6, 2023
Nasdaq First North, Faron Pharmaceuticals, AIM, Conference, Doctor of Philosophy, Cancer, Pharmaceutical industry, Online shopping

TURKU, Finland and BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.

Key Points: 
  • TURKU, Finland and BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.
  • In addition to the presentation, company management will be available for one-on-one meetings with investors.
  • For more information please contact:

Closing of Debt Financing

Retrieved on: 
Friday, September 1, 2023
TSX Venture Exchange, Convertible, Minority, AIM, Independent director, Related party transaction, Multilateral, Nasdaq First North, JLE, ECAM, Gold, Indian stock exchange, MI, Fossar de la Pedrera, Facility, Landsbankinn, GCAM, Rare-earth element, Security (finance), Bank, Note

“I am pleased to announce the successful closing of our debt funding package.

Key Points: 
  • “I am pleased to announce the successful closing of our debt funding package.
  • I would like to extend my thanks to our investors and debt funding partners.
  • We are working with a highly qualified team of professionals as we accelerate our progression to trial mining activities.
  • As such, the elements of the debt financing with Fossar (US$1.0 million off the Senior Debt Term Loans), Livermore Partners LLC (US$2.4 million of the Convertible Notes), and ECAM LP (US$16.0 million of the Convertible Notes) constitute Related Party Transactions in accordance with AIM Rule 13.

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

Retrieved on: 
Tuesday, August 29, 2023
Faron Pharmaceuticals, MCR, Survival, HMA, Bone marrow, Head, MBA, Congress, Nasdaq First North, Patient, MedRxiv, Majesty of the Seas, Executive, AIM, European Hematology Association, NK, Manuscript, Celgene, ORS, PD-1, FDA, IPF, Venetoclax, ODD, Cancer, American Association for Cancer Research, Immunotherapy, Antigen presentation, Biomarker, CR, Tuomo, Bristol Myers Squibb, MDS, EUR, AML, Azacitidine, CPA, Tumor microenvironment, Lithium, Pharmaceutical industry, Vaccine, Management, Security (finance), Rare-earth element, Medical imaging, Fårö, Phase, SOC

TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").

Key Points: 
  • Mr. Leopoldo Zambeletti stepped down from the Board to assume a business development consulting role at Faron.
  • TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").
  • "I am extremely proud of the progress we made in the first half of 2023,” said Dr. Markku Jalkanen, Chief Executive Officer of Faron.
  • On June 30, 2023, the Company had outstanding borrowings of EUR 9.8 million under a loan facility with IPF Partners which is subject to financial covenants.

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, August 29, 2023
Faron Pharmaceuticals, AIM, ODD, SOC, Disorder, Acute myeloid leukemia, MDS, Nasdaq First North, AML, Azacitidine, Fårö, Standard of care, Patient, Syndrome, Cancer, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Rare-earth element, Pharmaceutical industry, Phase

Expected completion of dose escalation, readout of enrichment cohorts, and Phase II initiation in Q4 2023

Key Points: 
  • Expected completion of dose escalation, readout of enrichment cohorts, and Phase II initiation in Q4 2023
    TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia (AML).
  • FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for rare disorders that affect fewer than 200,000 people in the U.S.
  • ODD provides Faron with certain benefits, such as market exclusivity upon regulatory approval if received, exemption of FDA application fees, and tax credits for qualified clinical trials.
  • “Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to develop bexmarilimab as a potential treatment for AML,” said Chief Medical Officer Dr. Marie-Louise Fjällskog.

GoLogiq Plans to Acquire Swedish Fintech Company, Fram Venture 7, and its Vietnamese SME-Lending Platform, DragonLend

Retrieved on: 
Thursday, August 17, 2023
HO, Nasdaq First North, Fintech, Small business, FRAM, Lazada, SME, Recruitment, MSME, World Bank, Sale, Gross domestic product, Acquisition, GDP, COVID-19, Developed country, MSME & Startups Forum - Bharat, OTC, Growth, Letter, Bank, Cryptocurrency, Ali Baba

The acquisition includes all of Fram Venture 7’s equity interest in its wholly-owned subsidiary, DragonLend , a lending platform for profitable small and medium-sized enterprises (SME) in Vietnam.

Key Points: 
  • The acquisition includes all of Fram Venture 7’s equity interest in its wholly-owned subsidiary, DragonLend , a lending platform for profitable small and medium-sized enterprises (SME) in Vietnam.
  • The acquisition is expected to complement GoLogiq’s existing fintech ecosystem, which encompasses a range of financial services, from payroll services to retirement investing.
  • DragonLend provides short-term (three to six months) working capital finance solutions to profitable Vietnamese SMEs.
  • Under the terms of the letter of intent, GoLogiq will acquire 100% of Fram Venture 7 and secure employment agreements with management.

Faron Pharmaceuticals Notice of Half-Year Financial Results

Retrieved on: 
Friday, August 4, 2023
Nasdaq First North, Faron Pharmaceuticals, AIM, Q&A, EEST, EDT, Cancer, BST

TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.

Key Points: 
  • TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
  • A live virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and James O’Brien, Chief Financial Officer, at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on the day of results.
  • For more information please contact:

Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Wednesday, August 2, 2023
Canaccord Genuity, Faron Pharmaceuticals, AIM, HMA, SOC, Immunotherapy, Acute myeloid leukemia, MDS, Nasdaq First North, AML, Standard of care, Patient, Syndrome, Cancer, FDA, BLA, Conference, Pharmaceutical industry, Online shopping

The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA).

Key Points: 
  • The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA).
  • The Company’s filing of its first Biologics License Application (BLA) to the FDA is planned for H1 2025.
  • A live webcast of the fireside chat can be found here and in the Investor Relations section of Faron’s website at https://www.faron.com/investors/results-presentations .
  • Following the completion of the event, a webcast replay of the fireside chat will be available on the website for 90 days.

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

Retrieved on: 
Wednesday, July 19, 2023
Calendar, Nasdaq First North, Faron Pharmaceuticals, AIM, ID, Cancer, Pharmaceutical industry

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study.

Key Points: 
  • TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study.
  • Wednesday, July 19, 2023, at 8:30 am ET.
  • The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201) 493-6780 for international callers and entering the conference ID: 13740209.
  • The live webcast presentation with accompanying slides will be accessible here and on the Investor Relations Calendar page of the Company’s website at www.faron.com/investors/calendar .